<DOC>
	<DOCNO>NCT00020397</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : Randomized phase II trial study effectiveness vaccine therapy treat patient refractory metastatic melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Refractory Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether immunologic response obtain administration ESO-1 peptide vaccine comprise class I , II , peptides HLA-A*201 HLA-DPB1*04 positive patient refractory metastatic melanoma express ESO-1 . - Determine toxicity vaccine patient . - Determine whether prior immunization vaccine result increase clinical responsiveness patient treat interleukin-2 . OUTLINE : Patients assign 1 3 group accord HLA type . - Group 1 ( HLA-A*201 HLA-DPB1*04 positive ) : Patients receive ESO-1 peptide vaccine comprise class I ( ESO-1:157-165 [ 165V ] ) class II ( ESO-1:161-180 ) peptides subcutaneously every 3 week 4 course absence disease progression unacceptable toxicity . - Group 2 ( HLA-A*201 positive HLA-DPB1*04 negative ) : Patients receive ESO-1 peptide vaccine group I comprise class I peptide . - Group 3 ( HLA-A*201 negative HLA-DPB1*04 positive ) : Patients receive ESO-1 peptide vaccine group I comprise class II peptide . Patients develop disease progression discontinue vaccination receive high-dose interleukin ( IL-2 ) IV 15 minute every 8 hour 4 day ( maximum 12 dos ) . Treatment IL-2 repeat every 10-14 day 4 course absence disease progression ( least 2 course ) unacceptable toxicity . Patients stable disease mixed partial response vaccination IL-2 therapy may eligible additional vaccine therapy . Patients complete response vaccine therapy eligible 1 additional treatment . Patients follow 3 week . PROJECTED ACCRUAL : A total 45-90 patient ( 15-30 per treatment group ) accrue study within 1 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic melanoma express ESO1 antigen Must progress prior standard treatment Measurable evaluable disease HLAA*201 HLADPB1*04 positive PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Platelet count least 90,000/mm^3 Hepatic : SGOT SGPT less 3 time normal Bilirubin great 1.6 mg/dL ( 3.0 mg/dL patient Gilbert 's syndrome ) Hepatitis B surface antigen negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : No cardiac ischemia* No myocardial infarction* No cardiac arrhythmias* NOTE : *For interleukin2 ( IL2 ) administration Pulmonary : No obstructive restrictive pulmonary disease ( IL2 administration ) Immunologic : No autoimmune disease No active primary secondary immunodeficiency HIV negative No active systemic infection Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No active major medical illness ( IL2 administration ) PRIOR CONCURRENT THERAPY : Biologic therapy : No prior ESO1 immunization Chemotherapy : Recovered prior chemotherapy Endocrine therapy : No concurrent systemic steroid therapy Radiotherapy : Recovered prior radiotherapy Surgery : Not specify Other : At least 3 week since prior systemic therapy cancer No concurrent systemic therapy cancer</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>